Slide 1: BioLargo - We Make Life Better
af a rs Biol.argo We Make Life Better April 3, 2023 OTCQB:BLGO Westminster, CA
Slide 2: We Make Life Better
We Make Life Better (y BioLargo GNMavronmera CLYRA SNR veciars Medical subsidiary - plan Eroreel Gun is to spin-out when ready
Slide 3: Quarterly Revenue (2021-2022)
QUARTERLY REVENUE (2021-2022) se Revenve MILLIONS 2021 2022 2023 "01 2023 evence number are preliminary asites ibjacto change pending 3 Trends are not necessarily indicative of future performance ‘rewew and audit by the company’s independent registered public accounting fm.
Slide 4: Debt vs. Revenue
DEBT VS. REVENUE Revenue -wDebt $35 $3.0 ; (estimate) 525 2 20 Q Ess so sos s. a a2 ey as a a2 ey as a 2021 2022 2023 ce mopar emenarcameny "01 2023 evence number are preliminary asites ibjacto change pending 7 Jeet styrene ar ie penny aioe
Slide 5: Net Loss vs. Revenue
NET LOSS VS. REVENUE sm Revenue eNet Loss $35 $3.0 ; (estimate) s25 2 s20 6 4 ncudes gus sto sos soo a 2 aa os a 2 oa os a 2021 2022 2023 oS Seay "01 2023 evence number are preliminary asites ibjacto change pending 5 (Bebop per epmaled ng erandlrompesrdanags gmeclerar sh
Slide 6: SG&A vs. Revenue
$35 33.0 525 SG&A VS. REVENUE sm Revenue HGRA (estimate) Zeon mest é 2 seoee Ess — . a
Slide 7: Net Cash Used in Operating Activities
$35 $3.0 $25 MILLIONS, NET CASH USED IN OPERATING ACTIVITIES Pe Revenue @eNet cash used in operating activities 2021 2022 Trends are not necessarily indicative of future performance "01 2023 evence number are preliminary asites ibjacto change pending Jeet styrene ar ie penny aioe
Slide 8: Net Stockholder's Equity (5 Years)
NET STOCKHOLDER'S EQUITY (5 YEARS) 2018 2022 MILLIONS. e Increase of >$4 million over five years Trends are not necessarily indicative of future performance
Slide 9: Additional Financial Information
Sue pres release dated March 20,2023 Additional Financial Information 4 * Q1 2023 preliminary revenues estimated to be 50% Consolidated greater than Q4 2022* Revenues + In Q4, company generated positive net cash used in operating activities for first time + Working capital of $1.6 million at year-en
Slide 10: Slide 10
Slide 11: Consumer pet odor product
Refelea)s Consumer pet odor product Product marketed and sold by our partners, award-winning consumer product experts (Ikigai Marketing Works) + ONM receives manufacturer's margin and a royalty on sales + Business strategy: ramp up sales and sell to a major consumer products company + ONM would rece
Slide 12: Sodium-Sulfur Battery
BioLargo Sodium- Sulfur Battery Compared to Lithium: + Competitive energy density + Safer + More thermally stable + More cost-effective + Unlimited charge/discharge cycles + 100% domestic supply possible + Far superior environmental outcomes +, Better option for long duration energy storage (LDES),
Slide 13: Contact
OTCOB: BLGO Contact: Dennis Calvert President & CEO BioLargo, Inc. 14921 Chestnut St. Westminster, CA 92683 (888) 400-2863 dc@BioLargo.com www.BioLargo.com The BioLargo Family of Companies BioLargo, nc a sustainable scence, technology &fullservice enviromental engineering company that makes life bet
Slide 14: Appendix - additional slides for Q&A reference
Appendix - additional slides for O&A reference
Slide 15: Carbon Filtration / Media Filtration
‘CARBON FILTRATION/ MEDIA FILTRATION Test data proves AEC capable of achieving “non-detect" status of all PFAS chemicals targeted by proposed EPA regulations
Slide 16: EPA Proposes First National Standard for PFAS in Drinking Water
— Biden-Harris Administration Proposes First- “== Ever National Standard to Protect Communities _ from PEAS in Drinking Water March 14,2023 Contact Information S EPAPress Office (press@ena.gov) WASHINGTON - Today, the Biden Harts Administration announced its proposing thefstever national drinking wa
Slide 17: Unsurpassed Odor Control
UNSURPASSED ODOR CONTROL Without Fragrances, Enzymes or Chlorine Compounds a ZS Cr iD) yeaDyne
Slide 18: Garratt-Callahan MLD Product Line
Garratt - Callahan MLD Product Line + Proven commercially ready at our water lab in Oak Ridge * Technology scaled up + Systems to be designed, fabricated, and integrated by BioLargo + Unique patented product only available through G-C & BioLargo + Several client contracts in negotiation now
Slide 19: The energy storage problem
The energy storage problem Unbalanced grid leads to brownouts and voltage spikes Sunny vs cloudy & night vs day sources suffer from Windy vs calm & precise range limits Wave energy has low density, low efficiency intermittency, making =» it hard to balance Nuclear 2challenges withithe leadieycle sup
Slide 20: The problem(s) with Lithium
The problem(s) with Lithium * Lithium-ion technology can be explosive * High risk of thermal runaway * Lithium based plants have a finite life as dendrites accumulate on the cathode, which ultimately make the lithium battery unusable with a need to replace batteries every 5 to 7 years * The price of
Slide 21: The market needs batteries that:
The market needs batteries that: Can be produced and sourced domestically Are cost effective Perform at large-scale \ Why BioLargo is positioned to do this...